

Management Changes in Israel to Strengthen and Accelerate Investment Activities in Singapore

Misgav, Israel – 30 January 2019 – The Trendlines Group Ltd. (the “**Company**”, and together with its subsidiaries, “**Trendlines**” or the “**Group**”) announced today that, pursuant to the Company’s announcement on 18 December 2018 regarding the Company’s intention to open a new Singapore-based innovation center focused on developing agrifood technologies, Dr. Nitza Kardish (“**Dr. Kardish**”), Chief Executive Officer of Trendlines Incubators Israel and Vice President of the Company, has accepted the position of Vice Chair at the planned Singapore-based innovation center. The Company will make such further announcement(s) to keep shareholders informed, as and when there are material updates or developments.

Dr. Kardish’s position in Trendlines Incubators Israel will be assumed by Mr. Barak Singer (“**Mr. Singer**”) as of 1 February 2019. Dr. Kardish will continue to serve as a Vice President of The Trendlines Group.

Mr. Singer has served as Vice President Business Development of Trendlines Incubators Israel for the past two years. He has more than 15 years of experience in management, business development, investment banking, and venture capital. Prior to joining Trendlines, Mr. Singer held a number of senior management positions, including Managing Director, Co-Head of Investment Banking, and Head of Healthcare at Tamir Fishman & Co., representing the Royal Bank of Canada’s (NYSE:RY) investment banking arm in Israel, RBC Capital Markets. He also served as VP Business Development at Can-Fite BioPharma Ltd. (NYSE: CANF) and CEO of its subsidiary OphthaliX Inc., VP Business Development at Xenia Venture Capital Ltd., and was a Co-Founder and CEO at Or Capital Healthcare Partners.

Mr. Singer received his LLB and BA in business (both with distinction) from the Interdisciplinary Center Herzliya in Israel.

The Company further announced today that Mr. Yosi Hazan (“**Mr. Hazan**”), CEO of Trendlines Labs, is leaving the Company to pursue other career opportunities. Mr. Hazan’s position will be assumed by Mr. Nir Goldenberg (“**Mr. Goldenberg**”), currently the VP Business Development of Trendlines Labs, effective as of 1 February 2019.

Mr. Goldenberg brings extensive international medical device sector experience in business development, sales, and marketing to the Company. In his position at Trendlines Labs for the past three years, Mr. Goldenberg has overseen the business development activities of the in-house innovation center. Trendlines Labs evaluates critical unmet clinical needs to innovate technological solutions to invent and develop products and technologies for Trendlines’ multinational partners or to create new companies to join Trendlines’ portfolio in Israel and Singapore.

Prior to joining Trendlines Labs, Mr. Goldenberg served as Director of Commercial Development EU at INSIGHTEC Ltd., a global MR-guided focused ultrasound surgery company.

Mr. Goldenberg holds a BSc in engineering from La Sapienza University of Rome.

The changes in the Company's management described above are expected to strengthen the overall structure of the Company and to accelerate the Company's investment and development activities in Singapore, which constitute an essential component in the overall strategic development of the Company.

About The Trendlines Group Ltd.

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

Investor Contact Information

Israel

Shira Zimmerman, The Trendlines Group

shira@trendlines.com

Tel: +972.72.260.7000

Singapore

Reyna MEI, Financial PR

reyna@financialpr.com.sg

Tel: +65.6438.2990

This press release has been prepared by The Trendlines Group Ltd. (the "Company") and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Associate Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg)

GENERAL ANNOUNCEMENT::PRESS RELEASE - MANAGEMENT CHANGES

Issuer & Securities

Issuer/ Manager

THE TRENDLINES GROUP LTD.

Securities

THE TRENDLINES GROUP LTD. - IL0011328858 - 42T

Stapled Security

No

Announcement Details

Announcement Title

General Announcement

Date &Time of Broadcast

30-Jan-2019 17:27:56

Status

New

Announcement Sub Title

Press Release - Management Changes

Announcement Reference

SG1901300THRPMN

Submitted By (Co./ Ind. Name)

Haim Brosh

Designation

Joint Company Secretary